Article
PARP inhibitors as precision medicine for cancer treatment
2017-03-14
Abstract excerpt
Abstract Personalized or precision medicine is an emerging treatment approach tailored to individuals or certain groups of patients based on their unique characteristics. These types of therapies guided by biomarkers tend to be more effective than traditional approaches, especially in cancer. The inhibitor against poly (ADP-ribose) polymerase (PARP), olaparib (Lynparza, AstraZeneca), which was approved by the US F...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 28d747bc-8456-5025-ac6a-2cf5bed7f353
- DOI
- 10.1093/nsr/nwx027
